Siemens Healthineers reported 4.0% comparable revenue growth for fiscal 2026 and adjusted EBIT of approximately €3.8 billion. The November 5 announcement shows different trajectories across its businesses.
Fourth-quarter imaging comparable growth reached 10.0%, while diagnostics declined 4.2%. Group-level growth therefore does not describe every segment equally.
Context and evidence
Financial results show demand and business performance rather than independent evidence of clinical effectiveness. Comparable growth and adjusted profit are company financial measures and should not be confused with unadjusted revenue or statutory earnings.
What it means
For the industry, the divergence highlights stronger imaging momentum alongside pressure in diagnostics. Procurement and clinical assessments still require product-specific evidence; financial strength is not a substitute for it.
Primary source: Original announcement. This report is based on company statements, not an independent clinical assessment.